Glivec 100 mg film-coated tablets

Product Information *

  • Company:

    Novartis Ireland Limited
  • Status:

    No Recent Update
  • Active Ingredients :

    This medicinal product is subject to additional monitoring.

    *Additional information is available upon request

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 07 May 2021

File name

Glivec-N-123 REGPIL PF21-0098_Clean_19.04.2021_1620393898.pdf

Reasons for updating

  • Individual PILs superseded by joint PIL

Updated on 01 July 2020

File name

IPHA Glivec FCT REGPIL PF 20-0128_Clean_1593601029.pdf

Reasons for updating

  • Change to section 2 - pregnancy, breast feeding and fertility

Updated on 01 July 2020

File name

Glivec FCT REGSPC PF 20-0128_Clean _1593599482.pdf

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 07 April 2020

File name

Glivec_100mg_REG PIL PF 19-0236 BRAIN Clean IPHA Aug 2019_1586253551.pdf

Reasons for updating

  • Change to name of manufacturer

Updated on 23 August 2019

File name

Glivec 100mg FCT Package Leaflet April 2019_1554377577.pdf

Reasons for updating

  • Change to section 6 - date of revision

Updated on 04 April 2019

File name

Glivec 100mg FCT Package Leaflet April 2019_1554377577.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions

Updated on 04 April 2019

File name

Glivec_100mg_400mg_FCTab_28-Mar-19_English_Clean _1554377309.pdf

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 20 July 2018

File name

REG_PIL_Glivec 100mg FCT_R91_WEH_p1_LFT_X-4_IPHA.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 21 February 2017

File name

PIL_8510_811.pdf

Reasons for updating

  • New PIL for new product

Updated on 21 February 2017

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 22 June 2016

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 08 May 2015

Reasons for updating

  • Change to side-effects

Updated on 29 April 2015

Reasons for updating

  • Change to warnings or special precautions for use
  • Addition of black triangle

Updated on 23 April 2014

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 30 July 2013

Reasons for updating

  • Change to date of revision

Updated on 27 September 2012

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to drug interactions
  • Change to MA holder contact details

Updated on 30 August 2011

Reasons for updating

  • Change to side-effects

Updated on 10 April 2007

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to, or new use for medicine

Updated on 10 January 2007

Reasons for updating

  • Change to, or new use for medicine

Updated on 12 July 2006

Reasons for updating

  • Change to side-effects

Updated on 02 November 2005

Reasons for updating

  • Change to side-effects
  • Change to dosage and administration

Updated on 25 August 2004

Reasons for updating

  • New PIL for medicines.ie